Announcements Trials
Browse Landscape

Phase

Phase NA 16Phase 3 2Phase 2/3 2Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 290Prostatic Neoplasms 192Neoplasm Metastasis 154Multiple Myeloma 147Colorectal Neoplasms 123Lung Neoplasms 104Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 88Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 80Stomach Neoplasms 76Small Cell Lung Carcinoma 72Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 66Pain 66Uterine Cervical Neoplasms 64Carcinoma, Renal Cell 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

Docosahexaenoic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Polyps × Clear all
NCT06950385 2026-05-22

SERENTA

Rapamycin Holdings Inc.

Phase 3 Recruiting
168 enrolled
Gastrointestinal

Adenomatous Polyposis Coli, Polyps

NCT03806426 2024-04-25

Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

S.L.A. Pharma AG

Phase 3 Unknown
204 enrolled
Gastrointestinal

Adenomatous Polyposis Coli, Polyps

Data powered by HemOnc (CC BY 4.0) Colophon âš¡